KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 10.32%.

  • Alnylam Pharmaceuticals' EBITDA Margin rose 260800.0% to 10.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 9.29%, marking a year-over-year increase of 221500.0%. This contributed to the annual value of 8.84% for FY2025, which is 217000.0% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' EBITDA Margin stood at 10.32%, which was up 260800.0% from 20.76% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBITDA Margin registered a high of 20.76% during Q3 2025, and its lowest value of 154.17% during Q3 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median EBITDA Margin value was 57.49% (recorded in 2022), while the average stood at 55.38%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 1744900bps in 2023, then crashed by -567600bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBITDA Margin stood at 99.6% in 2021, then soared by 38bps to 62.19% in 2022, then skyrocketed by 53bps to 29.32% in 2023, then surged by 46bps to 15.76% in 2024, then soared by 166bps to 10.32% in 2025.
  • Its EBITDA Margin was 10.32% in Q4 2025, compared to 20.76% in Q3 2025 and 7.59% in Q2 2025.